Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. With more than 80% of people who need a pacemaker requiring pacing in two chambers of the heart (both the right atrium and right ventricle), the approval significantly increases access to leadless pacing for millions of people across the U.S.[i]...
Giving access to a patented, innovative, and proven next-generation Drug Coated Balloon technology...
Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway. The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension....
At no additional cost to patients ...
Group Management Services (GMS), a leading professional employer organization (PEO) headquartered in Richfield, Ohio, is pleased to announce its partnership with Lumina Imaging and Diagnostics. This collaboration revolutionizes the health care landscape for GMS clients and their employees throughout Northeast Ohio....
System Allows Conversion to Reverse Shoulder Replacement Prosthesis...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and tTau assays (used as a tTau/Abeta42 ratio) measure two biomarkers of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease....
INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day inc...
Next-generation FDA-cleared medical device brings non-invasive heart and lung disease detection to healthcare professionals at the point of care ...
SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health....